कृपया अन्य खोज का प्रयास करें
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company’s ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Steven Kelly | 58 | 2023 | President, CEO & Director |
Sanford S. Zweifach | 67 | 2023 | Independent Chairman of the Board |
Regina Hodits | 55 | 2023 | Independent Director |
Nina Bhardwaj | - | 2020 | Member of Scientific Advisory Board |
Briggs W. Morrison | 64 | 2023 | Independent Director |
Padmanee Sharma | - | 2023 | Member of Scientific Advisory Board |
Carl H. June | 70 | - | Member of Scientific Advisory Board |
Lisa M. Coussens | - | - | Member of Scientific Advisory Board |
Saar Gill | - | - | Co-Founder & Chairman of Scientific Advisory Board |
Prasad S. Adusumilli | - | 2020 | Member of Scientific Advisory Board |
Michael Patrick Torok | 45 | 2023 | Independent Director |
Björn Odlander | 66 | 2023 | Independent Director |
Hyam I. Levitsky | 66 | - | Member of Scientific Advisory Board |
Lin Guey | - | 2023 | Member of Scientific Advisory Board |
John A. Hohneker | 64 | 2024 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है